Markets
Baskets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
All Features
Widgets
More
Search stocks
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Overview
Buy Sell Zone
Financials
News
All
News
Earnings Calls
Corporate Announcements
Research Reports
Reports
Technicals
Technicals
Price History/Seasonality
Delivery
Shareholding
Shareholding
Monthly MF Holdings
Bulk Block Deals
Insider Trading & SAST
Deals
Bulk Block Deals
Insider Trading & SAST
Corporate Actions
All
Dividend
Bonus
Split
Rights
Board Meetings
Alerts
About
Caplin Point Laboratories Ltd.
NSE: CAPLIPOINT
|
BSE: 524742
|
ISIN: INE475E01026
|
Industry: Pharmaceuticals
US FDA Approval
|
Mid-range Performer
1728.6000
1.60
(
0.09
%)
NSE
Feb 26, 2026
15:31 PM
27.82% Fall from 52W High
Volume:
24,774
Share on Facebook
Tweet
Share on LinkedIn
Share via Whatsapp
Caplin Point Laboratories Ltd.
08 Aug 2024
US FDA Approval
1728.60
0.09%
Caplin Point Laboratories
Buy:
Caplin Point Laboratories ...
by
ICICI Direct
Target: 1980
Target
ICICI Direct
Number of FII/FPI investors decreased from 190 to 174 in Dec 2025 qtr
More from Caplin Point Laboratories Ltd.
Recommended
Profit expectations across industries grow more sensitive to costs
The Baseline |
26 Feb 2026, 06:30PM
We tracked 5 years of IPOs. Some hard truths for investors about returns
The Baseline |
26 Feb 2026, 04:43PM
Caplin Point Laboratories maintains export momentum, expands ambitions to new markets
|
01 Jul 2022